X T L Biopharmaceuticals Ltd (XTLB) is not a good buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, there are no significant trading trends, no positive news catalysts, and the company's financial performance shows declining net income. Additionally, there are no strong proprietary trading signals to suggest immediate action.

Technical Analysis

The MACD is negative and expanding downward (-0.0203), indicating bearish momentum. The RSI is at 23.675, which is neutral but leaning toward oversold. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 0.731, and resistance is at 1.006, with the current price at 0.7617, close to support.

Positive Catalysts

NULL. There are no recent news updates, no significant insider or hedge fund activity, and no proprietary trading signals.

Neutral/Negative Catalysts

Bearish technical indicators, declining net income (-10.21% YoY), and lack of trading or news momentum.

Financial Performance

In Q4 2024, revenue remained flat at $289,000 (0.00% YoY), net income dropped to -$255,000 (-10.21% YoY), EPS remained at -0.01 (0.00% YoY), and gross margin is negative at -12.19 (0.00% YoY). Overall, financial performance is weak with no signs of growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast XTLB stock price to rise

Buy

Hold

Sell

Current: 0.763

Low

Averages

High